Drug Patents owned by Teva Branded Pharm

1. Drug name - AUSTEDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

CN104311552A TEVA BRANDED PHARM Vesicular Monoamine Transporter 2 Benzoquinoline Inhibitor
Nov, 2016

(5 years ago)

CN104684555A TEVA BRANDED PHARM Preparation Medicine Dynamics Vesicle Single Ammine Transport Body Deuterated Benzene And 2 Quinoline And Its Inhibitor
Oct, 2020

(2 years ago)

CN102186848A TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

CN102186848B TEVA BRANDED PHARM Benzene Quinoline And Inhibitor Of Vesicle Monoamine Transporter Body 2
Sep, 2029

(6 years from now)

IN296447B TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2326643B1 TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP3061760B1 TEVA BRANDED PHARM Deuterated Benzoquinolizine Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2610254A1 TEVA BRANDED PHARM Deuterated Benzoquinoline Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2326643A2 TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP3345905B1 TEVA BRANDED PHARM Deuterated Benzoquinolizine Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2610254B1 TEVA BRANDED PHARM Deuterated Benzoquinoline Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP3061760A1 TEVA BRANDED PHARM Deuterated Benzoquinolizine Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP3345905A1 TEVA BRANDED PHARM Deuterated Benzoquinolizine Derivatives As Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

EP2326643A4 TEVA BRANDED PHARM Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
Sep, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2 Oct, 2031

(9 years from now)

US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Mar, 2034

(11 years from now)

US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders Mar, 2036

(13 years from now)

US10959996

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders Sep, 2036

(13 years from now)

US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use Mar, 2038

(15 years from now)

US11179386

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use Sep, 2038

(15 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia; a method of treating huntington's chorea

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
6MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

2. Drug name - LOSEASONIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jun, 2023

(8 months from now)

US7858605 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jun, 2023

(8 months from now)

US7855190 TEVA BRANDED PHARM Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration Dec, 2028

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.02MG,0.1MG;0.01MG,N/A TABLET;ORAL Prescription

3. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA BRANDED PHARM Reservoir pressure system for medicament inhaler May, 2023

(6 months from now)

US10765820 TEVA BRANDED PHARM Dry powder inhalation apparatus May, 2025

(2 years from now)

US9463288 TEVA BRANDED PHARM Dry powder inhalation apparatus May, 2025

(2 years from now)

US8651103 TEVA BRANDED PHARM Dry powder inhalation apparatus Mar, 2028

(5 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10124131 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US9731087 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

US9216260 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jun, 2031

(8 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

US8978966 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof Jan, 2032

(9 years from now)

US9782550 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2035

(12 years from now)

US9782551 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2035

(12 years from now)

US10918816 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler Dec, 2035

(13 years from now)

US10569034 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2036

(13 years from now)

US11000653 TEVA BRANDED PHARM Inhaler Dec, 2038

(16 years from now)

US11173259 TEVA BRANDED PHARM Drug delivery device with electronics and power management Jul, 2040

(17 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

4. Drug name - PROAIR HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7105152 TEVA BRANDED PHARM Suspension aerosol formulations Sep, 2023

(11 months from now)

US8132712 TEVA BRANDED PHARM Metered-dose inhaler Sep, 2028

(5 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses May, 2031

(8 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH AEROSOL, METERED;INHALATION Prescription

5. Drug name - QNASL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7780038 TEVA BRANDED PHARM Dispensing apparatus with dosage counter Jan, 2027

(4 years from now)

US10188811 TEVA BRANDED PHARM Nasal spray device Oct, 2031

(9 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.04MG/ACTUATION AEROSOL, METERED;NASAL Prescription
0.08MG/ACTUATION AEROSOL, METERED;NASAL Prescription

6. Drug name - QUARTETTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450299 TEVA BRANDED PHARM Methods of hormonal treatment utilizing ascending-dose extended cycle regimens Oct, 2025

(3 years from now)

US8415332 TEVA BRANDED PHARM Methods of hormonal treatment utilizing ascending-dose extended cycle regimens Mar, 2029

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A TABLET;ORAL Prescription

7. Drug name - QVAR 40

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses May, 2031

(8 years from now)

US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement May, 2031

(8 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof May, 2031

(8 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator Jan, 2032

(9 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.04MG/INH AEROSOL, METERED;INHALATION Discontinued
0.08MG/INH AEROSOL, METERED;INHALATION Discontinued

8. Drug name - SEASONIQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jun, 2023

(8 months from now)

US7858605 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jun, 2023

(8 months from now)

US7320969 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Jan, 2024

(1 year, 3 months from now)

US7855190 TEVA BRANDED PHARM Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration Dec, 2028

(6 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.03MG,0.01MG;0.15MG,N/A TABLET;ORAL Prescription

9. Drug name - VANTRELA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572803 TEVA BRANDED PHARM Abuse resistant drug formulation Sep, 2027

(4 years from now)

US9216176 TEVA BRANDED PHARM Abuse resistant drug formulation Sep, 2027

(4 years from now)

US8445018 TEVA BRANDED PHARM Abuse resistant drug formulation Jul, 2029

(6 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
45MG TABLET, EXTENDED RELEASE;ORAL Discontinued
60MG TABLET, EXTENDED RELEASE;ORAL Discontinued
90MG TABLET, EXTENDED RELEASE;ORAL Discontinued

10. Drug name - ZECUITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6745071 TEVA BRANDED PHARM Iontophoretic drug delivery system Feb, 2023

(4 months from now)

US8155737 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration Apr, 2027

(4 years from now)

US8597272 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration Apr, 2027

(4 years from now)

US8470853 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds Apr, 2027

(4 years from now)

US9427578 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration Apr, 2027

(4 years from now)

US7973058 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds Apr, 2027

(4 years from now)

US9272137 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds Sep, 2027

(4 years from now)

US8366600 TEVA BRANDED PHARM Polyamine enhanced formulations for triptan compound iontophoresis Apr, 2029

(6 years from now)

US8983594 TEVA BRANDED PHARM Electronic control of drug delivery system Nov, 2030

(8 years from now)

US9327114 TEVA BRANDED PHARM User-activated self-contained co-packaged iontophoretic drug delivery system Oct, 2032

(10 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation

Dosage: SYSTEM;IONTOPHORESIS

More Information on Dosage
Strength Dosage Availability
EQ 6.5MG BASE/4HR SYSTEM;IONTOPHORESIS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.